Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, today announces it has appointed Sheryl Caswell as Clinical Development Manager. Sheryl will be responsible for leading and executing the company's clinical development strategy focused on the company's two main medicines reformulation programmes in NSAIDs and Statins with reduced side effects. Sheryl will be a member of Oxford Pharmascience's management team reporting to Marcelo Bravo, chief technology officer.
Sheryl has more than 15 years of experience developing and executing global clinical programs for novel and first-in-class products from Phase I through Phase IV, with particular experience in early phase clinical development. Most recently as Clinical Programme Lead at Biogen Idec Ltd, she led the clinical programmes of two of the company's product candidates in neurology. Prior to that she served as Programme Director and Director of Clinical Research for Plethora Solutions where she led the clinical function as well as had overall clinical development responsibility for early phase products.
"Sheryl Caswell is joining Oxford Pharmascience at an exciting time in the company's evolution. We are progressing to human proof of concept trials in both our NSAIDs and Statin programmes and Sheryl will play a key role in making this happen," said Marcelo Bravo, Chief Technology Officer. "We look forward to leveraging Sheryl's extensive global clinical development experience as we advance our two main programmes in reformulation of NSAIDs and Statins with reduced side effects".
For further information:
Oxford Pharmascience Group Plc
Nigel Theobald, Chief Executive +44 (0) 207 554 5875
Shaun Dobson/Jenny Wyllie +44 20 7496 3000
About Oxford Pharmascience Group Plc
Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.
Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.